Filgrastim Biosimilar (VA-27-00012533)

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NAC PHARMACEUTICALS (36E797)

Contract Value

Not provided

Codes & Classification
Solicitation Number

36E79727R0001

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents1
The Department of Veterans Affairs (VA), through its NAC Pharmaceuticals office, has issued a presolicitation notice for the procurement of a Filgrastim biosimilar, under procurement identifier 36E79727R0001. This opportunity is classified under NAICS code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and carries the product service code 6505, indicating a focus on drugs and biologicals. The primary purpose of this procurement is to secure a reliable supply of Filgrastim biosimilar for VA medical facilities, supporting the agency’s mission to provide high-quality pharmaceutical care to veterans. Filgrastim is a critical therapeutic agent used to stimulate the production of white blood cells, often administered to patients undergoing chemotherapy or those with compromised immune systems. The intended outcome is to ensure consistent access to this essential medication, thereby enhancing patient care and treatment outcomes across the VA healthcare system. Key requirements and objectives for this procurement include the manufacturing and supply of Filgrastim biosimilar in accordance with federal standards and VA specifications. Contractors must demonstrate the capability to produce pharmaceutical preparations that meet rigorous quality, safety, and efficacy criteria. Expected deliverables will likely encompass the provision of Filgrastim biosimilar in specified formulations and quantities, with adherence to delivery schedules and regulatory compliance. The contracting entity for this opportunity is NAC Pharmaceuticals (36E797), a federal office within the Department of Veterans Affairs. The notice is currently active and accessible via SAM.gov, with further details and attachments available through the provided URL. Interested parties are encouraged to review the attached documents for comprehensive requirements and submission instructions. The procurement is structured as a presolicitation, indicating that formal solicitation documents and detailed specifications will be released in the future. Contractors should note the response deadline of December 15, 2026, and direct any inquiries to the primary contact, Dov Vysnia, at [email protected]. This opportunity is well-suited for manufacturers specializing in pharmaceutical preparations, particularly those with experience in biosimilars and federal contracting. The scope and requirements are expected to remain consistent throughout the contract lifecycle, focusing on the supply of Filgrastim biosimilar to support VA healthcare operations nationwide. For further information and to access the presolicitation notice, visit: https://sam.gov/opp/f6209618c8914b9c9d0453cf66a3a9ee/view.